Insulet Co. (NASDAQ:PODD) Shares Purchased by M&T Bank Corp

M&T Bank Corp raised its position in Insulet Co. (NASDAQ:PODD) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,061 shares of the medical instruments supplier’s stock after buying an additional 162 shares during the period. M&T Bank Corp’s holdings in Insulet were worth $2,108,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PODD. QRG Capital Management Inc. acquired a new stake in shares of Insulet in the third quarter worth approximately $297,000. Fisher Asset Management LLC boosted its stake in Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC grew its holdings in shares of Insulet by 86.2% during the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after buying an additional 3,623 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of Insulet in the second quarter worth about $554,000.

Insulet Trading Down 0.9 %

PODD opened at $269.34 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $18.89 billion, a P/E ratio of 46.12, a P/E/G ratio of 4.18 and a beta of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.77. The business has a fifty day simple moving average of $251.37 and a 200-day simple moving average of $220.31.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Canaccord Genuity Group upped their price target on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $267.44.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.